Advanced Targeting Systems Product Catalog

Total Page:16

File Type:pdf, Size:1020Kb

Advanced Targeting Systems Product Catalog AAddvvaanncceedd TTaarrggeettiinngg SSyysstteemmss PPrroodduucctt CCaattaalloogg Molecular Surgery for Scientists (877) 889-2288 toll-free 10451 Roselle Street, #300 (858) 642-1988 telephone www.ATSbio.com website San Diego, CA 92121 USA (858) 642-1988 fax [email protected] email Table of Contents Saporin ...........................................................5 Secondary Conjugates ................................21 Saporin ............................................................................5 Anti-M-ZAP (primary mouse monoclonal IgM )..............21 Anti-Saporin ....................................................................5 Fab-ZAP (primary mouse monoclonal IgG , monovalent )22 Targeted Toxins .............................................6 Goat-ZAP (primary goat monoclonal IgG ) ....................22 Hu g-M -ZAP (primary human monoclonal IgM ) .............23 192-IgG-SAP (rat NGFr ) .................................................6 Hum-ZAP (primary : human monoclonal IgG ) ...............23 Acetylated LDL-SAP (rat microglia ) ...............................7 Mab-ZAP (primary mouse monoclonal IgG ) .................24 Anti-CD22-SA P (human CD22 ) ......................................7 Anti-CD25-SAP (human CD25 ) .....................................8 Rab-ZAP (primary rabbit polyclonal IgG )......................24 Anti-CD25-SAP (mouse CD25 ) .....................................8 Rat-ZAP (primary rat monoclonal IgG ) .........................25 Anti-CD103-SAP (CD103) ...............................................9 Custom Conjugates ......................................................25 Anti-DAT-SAP (rat / human dopamine transporter ........9 Streptavidin-ZAP (biotinylated material ) .......................26 Anti-DBH-SAP (r at dopamine beta-hydroxylase )..........10 Biotinylation Service ......................................................26 Anti-SERT-SAP (rat / human SERT) .............................11 Bombesin-SAP (GRP receptor ).....................................11 Control Conjugates .....................................27 CTB-SAP (GM 1 Ganglioside ) .......................................12 Blank-SAP (for peptide conjugates )..............................27 CRF-SAP (CRF receptor 1 ) ..........................................12 Goat IgG-SAP ...............................................................28 CCK-SAP (CCKr1 and CCKr2 ).....................................12 Human IgG-SAP ...........................................................28 Dermorphin-SAP / MOR-SAP (MOR ) ...........................13 Mouse IgG-SAP ............................................................29 FGF-SAP (FGF receptor s) ............................................13 Mouse IgM-SAP ............................................................29 GAT1-SAP (GABA-1 transporter, GAT-1 )......................14 Rabbit IgG-SAP ............................................................30 Galanin-SAP (galanin-1 receptor ).................................14 Rat IgG-SAP .................................................................30 IB4-SAP (a-D-Galacto pyranoside residues ) .................15 Fluorescent Conjugates ..............................31 Leptin-SAP (leptin receptor )..........................................15 Custom Fluorescent Labeling .......................................32 Mac-1-SAP (mouse / human CD11b receptor ) .............16 Antibodies ....................................................34 Mac-1-SAP (rat CD11b receptor )..................................16 ME20.4-SAP (mammalian NGFr ) .................................17 Proteins, Peptides & Antigens ...................46 Melanopsin-SAP (melanopsin , ipRGCs ).......................17 Index .............................................................59 mu p75-SAP (mouse NGFr )..........................................18 NPY-SAP (neuropeptide Y receptor ).............................18 Oxytocin-SAP (oxytocin receptor ).................................19 OX7-SAP (multi-species Thy-1.1 ).................................19 SSP-SAP (substance P receptor ) .................................20 SP-CTA (substance P receptor )....................................20 Table of Contents 2 The Technology 3 Saporin 4 Targeted Toxins 5 Secondary Conjugates 20 Control Conjugates 26 Fluorescent Conjugates 30 Antibodies 33 Proteins, Peptides & Antigens 45 Index 58 Page 3 The Technology Follow these simple illustrations to understand how this advanced targeting system can work for you. Or watch a multi-media presentation demonstrating this technology at www.ATSbio.com/movie 1) 2) 3) 4) Get an antibody specific to your cell type. Use a potent toxin that is ATS puts them The conjugate seeks together out target markers Or use anything safe in the lab, to make a powerful on the cell surface. that binds to a cell but lethal inside a cell. targeting agent. surface molecule and is internalized. 5) 6) 7) 8) Once attached to its target receptor, the The bond between The ribosomes are conjugate is internalized. The SAPORIN SAPORIN and the inactivated Cells which do not have conjugate enters the targeting agent is resulting in the target receptor cell. broken in the cell death. will not be affected. endosome. Pretty simple, huh? Now just imagine the targets you can eliminate in your research! Page 4 Saporin (pronounced ) Saporin (Cat. #PR-01: 100 µg) Saporin is a ribosome-inactivating protein, molecular weight 30 kDa, from seeds of the plant Saponaria officinalis . Effective Tool • An experimental control with targeted toxins • Safe for laboratory use under normal safety conditions • LD 50 in mice at 4 mg/kg • Does not have a method of cell entry on its own Sample protocol For most targeted toxins, there are control conjugates available (pp. 23-25); these are the most accurate controls to use. For a few products, saporin is used as control. Calculate amount of saporin needed on a molar basis. For example, FGF-SAP (Cat. #IT-38) has an average mol. wt. of 63 kDa, and 71% of that is saporin (approximately 1.5 molecules of saporin per molecule of cytokine). For injections of 5 µg of immunotoxin, an appropriate control quantity would be 3.6 µg. Anti-Saporin (Cat. #AB-15; AB-15 AP ; AB-15 hRP ; AB-17 AP , AB-41 AP ) Specificity AB-1 5Ap Goat Anti-Saporin, • goat anti-saporin, 100 µl (Cat. #AB-15) affinity purified • goat anti-saporin affinity purified, 50 µg (Cat. #AB-15 AP ) Lane 1: Molecular weight standards (Invitrogen SeeBlue) • goat anti-saporin HRP-labeled, 200 µg (Cat. #AB-15 HRP ) Lane 2: 50 ng of Saporin • chicken anti-saporin affinity purified, 50 µg (Cat. #AB-17 AP ) probed with Goat anti-Saporin • rabbit anti-saporin affinity-purified, 50 µg (Cat. #AB-41 AP ) affinity purified (AB-15 Ap ) at 1.0 µg/ml Applications Lane 3: 25 ng of Saporin • immunoblotting, ELISA, immunohistochemistry probed with Goat anti-Saporin affinity purified (AB-15 Ap ) at 1.0 AB-1 5hrp Goat Anti- µg/ml Saporin, hrp-labeled Saporin (200, 100, 50, and 25 ng) was run on a 10% SDS-pAGE gel AB-17 Ap Chicken and transferred to pVDF membrane. Anti-Saporin, The blot was blocked with 4% affinity-purified NFM/TBS, then incubated overnight Lane 1: Molecular with 0.5 µg/ml (Lanes 11-15), 1 µg/ml weight standards (Lanes 6-10), or 5 µg/ml (Lanes 1-5) (Invitrogen of antibody. The blot was washed SeeBlue) and developed with 4-chloro-1- naphthol and hydrogen peroxide. Lane 2: 100 ng of Saporin probed Lane 1, 6, 11: Molecular weight with AB-17 Ap at a standards (Invitrogen SeeBlue) concentration of Lane 2, 7, 12: 200 ng Saporin 0.5 µg/ml Lane 3, 8, 13: 100 ng Saporin Lane 4, 9, 14: 50 ng Saporin Page 5 Lane 5, 10, 15: 25 ng Saporin Targeted Toxins 192-IgG-SAP TARGET: rat NGFr a chemical conjugate of a mouse monoclonal antibody to rat p75 NTR and the ribosome-inactivating protein, saporin Intraventricular injection of 192-IgG-SAP results in almost complete elimination of low affinity nerve growth factor receptor (p75 NTR )-positive cells in the rat basal forebrain. This immunotoxin provides researchers with a powerful lesioning tool — more specific and effective than chemical, surgical or electrolytic lesioning. 192-IgG-SAP (conjugate alone) Cat # Units IT-01-25 25 micrograms IT-01-100 100 micrograms IT-01-250 250 micrograms Kit: conjugate and controls (saporin, control conjugate) CONTrOL TrEATED Cat # Units p75 NTR -positive neurons of rat cholinergic icv injection of 192-Saporin KIT-01-25 25 micrograms forebrain >95% elimination of target neurons KIT-01-100 100 micrograms Photos supplied by C. Wrenn, R.G. Wiley KIT-01-250 250 micrograms related products: Cy3-labeled 192-IgG (Cat. #FL-01), Alexa488-labeled 192-IgG (Cat. #FL-03), Mouse IgG-SAp (Cat. #IT-18), mu p75-SAp (Cat. #IT-16), ME20.4-SAp (Cat. #IT-15) Page 6 Acetylated LDL-SAP TARGET: rat microglia a chemical conjugate of acetylated human low density lipoprotein and the ribosome-inactivating protein, saporin Acetylated LDL-Saporin (acetylated LDL-SAP) has been used effectively to eliminate microglia from primary cultures of rat hippocampal neurons, while having no deleterious effect on neurons or astroglia. After 24 hours exposure, 3 µg/ml of acetylated-LDL-SAP selectively kills more than 90% of microglia cells. Acetylated LDL-SAP (conjugate alone) Cat # Units IT-08-25 25 micrograms IT-08-100 100 micrograms IT-08-250 250 micrograms Kit: conjugate and control (saporin) Cat # Units NR8383 cells are plated at 10 4 cells/well and incubated overnight. KIT-08-25 25 micrograms Saporin and acLDL-SAp are added in 10-µl volumes and the plates are KIT-08-100 100 micrograms
Recommended publications
  • Hypocretin-2-Saporin Lesions of the Lateral Hypothalamus Produce Narcoleptic-Like Sleep Behavior in the Rat
    The Journal of Neuroscience, September 15, 2001, 21(18):7273–7283 Hypocretin-2-Saporin Lesions of the Lateral Hypothalamus Produce Narcoleptic-Like Sleep Behavior in the Rat Dmitry Gerashchenko,1 Matthew D. Kohls,4 MaryAnn Greco,1 Nahid S. Waleh,3 Rafael Salin-Pascual,1,2 Thomas S. Kilduff,3 Douglas A. Lappi,4 and Priyattam J. Shiromani1 1West Roxbury Veterans Affairs Medical Center and Harvard Medical School, West Roxbury, Massachusetts 02132, 2Facultad de Medicina, Universidad Nacional Auto´nomadeMe´ xico, Mexico City, Mexico 04510, 3SRI International, Menlo Park, California 94025, and 4Advanced Targeting Systems, San Diego, California 92121 Hypocretins (Hcrts) are recently discovered peptides linked to fected with the substance P (neurokinin-1) receptor. Adminis- the human sleep disorder narcolepsy. Humans with narcolepsy tration of the toxin to the LH, in which the receptor is known to have decreased numbers of Hcrt neurons and Hcrt-null mice be present, eliminated some neurons (Hcrt, melanin- also have narcoleptic symptoms. Hcrt neurons are located only concentrating hormone, and adenosine deaminase-containing in the lateral hypothalamus (LH) but neither electrolytic nor neurons) but not others (a-melanocyte-stimulating hormone), pharmacological lesions of this or any other brain region have indicating specificity of the toxin in vivo. When the toxin was produced narcoleptic-like sleep, suggesting that specific neu- administered to the LH, rats had increased slow-wave sleep, rons need to be destroyed. Hcrt neurons express the Hcrt rapid-eye movement (REM) sleep, and sleep-onset REM sleep receptor, and to facilitate lesioning these neurons, the endog- periods. These behavioral changes were negatively correlated enous ligand hypocretin-2/orexin B (Hcrt2) was conjugated to with the loss of Hcrt-containing neurons but not with the loss of the ribosome-inactivating protein saporin (SAP).
    [Show full text]
  • Advanced Targeting Systems Is Not Liable for Any Damages Resulting from the Misuse Or Handling of This Product
    ADVANCED 11175-A FLINTKOTE AVENUE, SAN DIEGO, CA 92121 TELEPHONE (858) 642-1988 • FAX (858) 642-1989 TARGETING WWW.ATSBIO.COM • [email protected] SYSTEMS mu p75-SAP (murine p75NTR-saporin) TARGETED TOXIN Catalog Number: IT-16 Quantity: 50 micrograms, 100 micrograms, 250 micrograms Format: PBS (0.14 M Sodium Chloride; 0.003 M Potassium Chloride; 0.002 M Potassium Phosphate; 0.01 M Sodium Phosphate; pH 7.4), no preservative. Sterile-filtered. Background: Targeted toxins are powerful and specific lesioning agents used in the technique known as Molecular Neurosurgery. The ribosome-inactivating protein, saporin (from the seeds of the plant, Saponaria officinalis) is bound to a targeting agent (antibody, growth factor, peptide, ligand, or cytokine). The targeted toxin is administered to the cells (in vitro or in vivo). The targeting agent seeks out and binds to its target on the cell surface. The conjugate is internalized, saporin breaks away from the targeting agent, and inactivates the ribosomes which causes protein inhibition and, ultimately, cell death. Cells which do not have the cell surface marker are not affected. Specificity and Preparation: This targeted toxin (molecular weight 210kDa) recognizes p75NTR-bearing cells in mouse. mu p75-SAP is a chemical conjugate of the rat monoclonal antibody p75NTR and the ribosome-inactivating protein, saporin (Saponaria officinalis). This product is routinely tested by cytotoxicity assay. Usage and Storage: mu p75-SAP specifically eliminates p75NTR-positive cells. Note that the concentration of this material is extremely high. This is necessary to be able to deliver, in a small volume, a sufficient amount. Due to this high concentration, the material should be handled with extreme care.
    [Show full text]
  • Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins
    toxins Review Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins Francesco Giansanti 1 ID , David J. Flavell 2, Francesco Angelucci 1, Maria Serena Fabbrini 3 and Rodolfo Ippoliti 1,* 1 Department of Life, Health and Environmental Sciences, University of L’Aquila, I-67100 L’Aquila, Italy; [email protected] (F.G.); [email protected] (F.A.) 2 The Simon Flavell Leukaemia Research Laboratory (Leukaemia Busters), Southampton General Hospital, Southampton, SO16 8AT, UK; [email protected] 3 Italian Ministry of Education, I-20100 Milano, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-086-243-3286 Received: 16 December 2017; Accepted: 11 February 2018; Published: 13 February 2018 Abstract: Plant Ribosome-inactivating proteins (RIPs) including the type I RIP Saporin have been used for the construction of Immunotoxins (ITxs) obtained via chemical conjugation of the toxic domain to whole antibodies or by generating genetic fusions to antibody fragments/targeting domains able to direct the chimeric toxin against a desired sub-population of cancer cells. The high enzymatic activity, stability and resistance to conjugation procedures and especially the possibility to express recombinant fusions in yeast, make Saporin a well-suited tool for anti-cancer therapy approaches. Previous clinical work on RIPs-based Immunotoxins (including Saporin) has shown that several critical issues must be taken into deeper consideration to fully exploit their therapeutic
    [Show full text]
  • Neuronal Lesioning with Axonally Transported Toxins
    Journal of Neuroscience Methods 103 (2000) 73–82 www.elsevier.com/locate/jneumeth Neuronal lesioning with axonally transported toxins Ronald G. Wiley a,*, Robert H. Kline IV b a Departments of Neurology and Pharmacology, Vanderbilt Uni6ersity, VAMC Nash6ille, TN 37212-2637, USA b Laboratory of Experimental Neurology, VAMC Nash6ille, TN 37212-2637, USA Received 17 March 2000; accepted 5 July 2000 Abstract Axonally transported toxins can be used to make selective lesions of the nervous system. Collectively, these techniques are termed ‘molecular neurosurgery’ because they exploit the surface molecular identity of neurons to selectively destroy specific types of neurons. Suicide transport, is anatomically selective but not type-selective. The most widely used suicide transport agents are the toxic lectins (ricin, volkensin) and the immunotoxin, OX7-saporin. The toxic lectins and saporin are ribosome inactivating proteins that irreversibly inhibit protein synthesis. The toxic lectins have binding subunits but saporin requires a targeting vector to gain entrance into cells. Immunolesioning uses monoclonal anti-neuronal antibodies to deliver saporin selectively into neurons that express a particular target surface antigen. Neuropeptide–saporin conjugates selectively destroy neurons expressing the appropriate peptide receptors. Notable experimental uses of these agents include analysis of the function of the cholinergic basal forebrain (192-saporin) and pain research (anti-DBH-saporin, substance P-saporin). It is likely that more immunolesioning and neuropeptide-toxin conjugates will be developed in the near future. © 2000 Published by Elsevier Science B.V. Keywords: Suicide transport; Immunolesioning; Saporin; Ribosome inactivating proteins; Molecular neurosurgery Functional neuroanatomy research has long relied on been used to produce selective lesions of neurons based analysis of the effects of lesions to infer the function of on the neurotransmitters secreted, but each of these neural structures.
    [Show full text]
  • CD7 Immunotoxins in Human T-Cell Acute Lymphoblastic Leukaemia Cells
    Antibodies 2013, 2, 50-65; doi:10.3390/antib2010050 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Article Dissecting the Entry Route of Saporin-based -CD7 Immunotoxins in Human T-Cell Acute Lymphoblastic Leukaemia Cells Francesco Giansanti 1, Valeria Giordani 1, Riccardo Vago 2, David J. Flavell 3, Sopsamorn U. Flavell 3, Maria Serena Fabbrini 4,* and Rodolfo Ippoliti 1,* 1 Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, I-67100, Italy 2 Dibit-HSR Scientific Institute and Università Vita-Salute San Raffaele, Milano, I-20132, Italy 3 The Simon Flavell Leukaemia Research Laboratory, Southampton General Hospital, Southampton, Hampshire SO16 6YD, UK 4 Istituto Nazionale di Genetica Molecolare-INGM, Milano, I-20122, Italy * Authors to whom correspondence should be addressed; E-Mails: [email protected] (M.S.F.); [email protected] (R.I.); Tel.: +39-086-243-3286 (R.I.); Fax: +39-086-243-3273 (R.I.). Received: 26 November 2012; in revised form: 31 December 2012 / Accepted: 7 January 2013 / Published: 16 January 2013 Abstract: Elucidating the intracellular fate(s) of targeted toxins is of fundamental importance for their optimal use as anticancer drugs, since the biochemical targets of their enzymatic activity reside in the cell cytoplasm, as in the case of the plant ribosome inactivating proteins (RIP) saporin, ricin and of bacterial toxins. In this paper, we compared the cell surface binding and cytotoxic properties of the model RIP ricin to an immunotoxin constructed with a monoclonal antibody directed against the human T-cell marker CD7 covalently linked to saporin (CD7-SAP).
    [Show full text]
  • Neurons Coexpressing Cholecystokinin-2 and Μ
    Pain Facilitatory Cells in Rostral Ventromedial Medulla: Neurons Coexpressing Cholecystokinin-2 and Mu-Opioid Receptors Item Type text; Electronic Dissertation Authors Zhang, Wenjun Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 18:17:21 Link to Item http://hdl.handle.net/10150/195291 1 PAIN FACILITATORY CELLS IN ROSTRAL VENTROMEDIAL MEDULLA: NEURONS COEXPRESSING CHOLECYSTOKININ-2 AND μ-OPIOID RECEPTORS By Wenjun Zhang A Dissertation Submitted to the Faculty of the COMMITTEE ON PHARMACOLOGY AND TOXICOLOGY (GRADUATE) In Partial Fulfillment of the Requirement For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2005 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by Wenjun Zhang entitled “Pain facilitatory cells in rostral ventromedial medulla: neurons coexpressing cholecystokinin-2 and mu-opioid receptors” and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy Josephine Lai, Ph.D __________________________________________________Date: Nov. 28, 2005 Edward French, Ph.D _________________________________________________Date: Nov. 28, 2005 Frank Porreca, Ph.D___________________________________________________ Date: Nov. 28, 2005 Naomi Rance, M.D, Ph.D_____________________________________________Date: Nov. 28, 2005 Todd Vanderah, Ph.D__________________________________________________Date: Nov. 28, 2005 Final approval and acceptance of this dissertation is contingent upon the candidate’s submission of the final copies of the dissertation to the Graduate College.
    [Show full text]
  • Cholinergic Signalling in the Forebrain Controls Microglial Phenotype and Responses to Systemic Inflammation
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427123; this version posted January 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Cholinergic signalling in the forebrain controls microglial phenotype and responses to systemic inflammation Arshed Nazmi, Eadaoin W. Griffin, Robert H. Field, Sean Doyle1, Edel Hennessy, Martin O’Donnell, Aisling Rehill, Anthony McCarthy, Daire Healy, Michelle M. Doran1, John P. Lowry1, Colm Cunningham School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute & Trinity College Institute of Neuroscience, Trinity College Dublin. 1Department of Chemistry, Maynooth University, Maynooth, Co. Kildare, Rep. of Ireland. Address for correspondence Colm Cunningham [email protected] +353 1 896 3964 Keywords Acetylcholine, microglia, priming, delirium, sepsis, neuroinflammation, bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427123; this version posted January 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract (250) Loss of basal forebrain cholinergic projections occurs in Alzheimer’s disease, frontotemporal dementia and in aging. Moreover, nicotinic stimulation is anti- inflammatory in macrophages and microglia but how loss of basal forebrain acetylcholine impacts on microglial phenotype is poorly understood. Here we hypothesized that endogenous ACh maintains homeostatic microglial phenotype and that neurodegeneration-evoked loss of ACh tone, triggers microglial activation.
    [Show full text]
  • The Effect of Small Molecule Pharmacological Agents on The
    biomedicines Article The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells Harrison J. Wensley 1,2, Wendy S. Smith 2 , Suzanne E. Holmes 2, Sopsamorn U. Flavell 2,3 and David J. Flavell 2,3,* 1 Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK; [email protected] 2 The Simon Flavell Leukaemia Research Laboratory, Southampton General Hospital, Southampton SO16 6YD, UK; [email protected] (W.S.S.); [email protected] (S.E.H.); [email protected] (S.U.F.) 3 Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK * Correspondence: [email protected] Abstract: Triterpenoid saponins augment the cytotoxicity of saporin based immunotoxins. It is postulated that this results from a saponin-mediated increase in the endolysosomal escape of the toxin to the cytosol, but this remains to be confirmed. To address this issue, we used a number of Citation: Wensley, H.J.; Smith, W.S.; pharmacological inhibitors of endocytic processes as probes to investigate the role played by saponin Holmes, S.E.; Flavell, S.U.; Flavell, D.J. in the endolysosomal escape of fluorescently labeled saporin and a saporin based immunotoxin The Effect of Small Molecule targeted against CD38 on human lymphoma and leukemia cell lines. Endolysosomal escape of the Pharmacological Agents on the toxin was measured by flow cytometric pulse shape analysis. These results were compared to the Triterpenoid Saponin Induced effects of the various inhibitors on the saponin-mediated augmentation of toxin and immunotoxin Endolysosomal Escape of Saporin cytotoxicity.
    [Show full text]
  • Delivery of Saporin to Human B-Cell Lymphoma Using Bispecific Antibody: Targeting Via CD22 but Not CD19, CD37, Or Immunoglobulin Results in Efficient Killing1
    [CANCER RESEARCH 53. 3015-3021. July I. 1993) Delivery of Saporin to Human B-Cell Lymphoma Using Bispecific Antibody: Targeting via CD22 but not CD19, CD37, or Immunoglobulin Results in Efficient Killing1 M. Antonietta Bonardi, R. R. French, P. Amlot, G. Gromo, D. Modena, and M. J. Glennie2 Lvmphoma Research Unit. Tenovus Laboratory. General Hospital. Southampton SO9 4XY, United Kingdom [M. A. B.. R. R. F.. M. J. G.I; Italfarmaco Centro Ricerche. 20092 Cinisello Balsama. Ml. Italy ¡M.A. B., G. G., D. M.¡;and Department of Immunology. Royal Free Hospital. London NW3 2OG. United Kingdom ¡P.A.I ABSTRACT The major disadvantage of this approach is that, because the toxin A panel of bispecific F(ab')2 antibodies (BsAb) have been constructed is carried through relatively weak, reversible, noncovalent interac tions, it may be released before entering the target cells. Two maneu for delivering the ribosome-inactivating protein saporin to human B cell vers have helped us safeguard against this shortcoming; first, before Ivmphoma. Each derivative was prepared with specificity for saporin and administration the BsAb-toxin complexes are formed with a signifi CD19, CD22, CD37, or immunoglobulin. In vitro studies measuring inhi bition of [3H]leucine uptake by cultured Daudi and Raji cells demon cant molar excess of BsAb, which greatly reduces the opportunity for strated that, despite all BsAb capturing saporin on the cell surface, BsAb free toxin to exist (10), and, second, the avidity with which the toxin targeting through CD22 were far more cytotoxic than those functioning binds to the target cells is increased by using pairs of BsAb, selected via CD19, CD37, or surface immunoglobulin.
    [Show full text]
  • Saporin-S6: a Useful Tool in Cancer Therapy
    Toxins 2013, 5, 1698-1722; doi:10.3390/toxins5101698 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Saporin-S6: A Useful Tool in Cancer Therapy Letizia Polito *, Massimo Bortolotti, Daniele Mercatelli, Maria Giulia Battelli and Andrea Bolognesi Department of Experimental, Diagnostic and Specialty Medicine-DIMES; Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; E-Mails: [email protected] (M.B.); [email protected] (D.M.); [email protected] (M.G.B.); [email protected] (A.B.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-0512094723; Fax: +39-0512094746. Received: 19 July 2013; in revised form: 17 September 2013 / Accepted: 22 September 2013 / Published: 7 October 2013 Abstract: Thirty years ago, the type 1 ribosome-inactivating protein (RIP) saporin-S6 (also known as saporin) was isolated from Saponaria officinalis L. seeds. Since then, the properties and mechanisms of action of saporin-S6 have been well characterized, and it has been widely employed in the construction of conjugates and immunotoxins for different purposes. These immunotoxins have shown many interesting results when used in cancer therapy, particularly in hematological tumors. The high enzymatic activity, stability and resistance to conjugation procedures and blood proteases make saporin-S6 a very useful tool in cancer therapy. High efficacy has been reported in clinical trials with saporin-S6-containing immunotoxins, at dosages that induced only mild and transient side effects, which were mainly fever, myalgias, hepatotoxicity, thrombocytopenia and vascular leak syndrome. Moreover, saporin-S6 triggers multiple cell death pathways, rendering impossible the selection of RIP-resistant mutants.
    [Show full text]
  • Dianthin and Its Potential in Targeted Tumor Therapies
    toxins Review Dianthin and Its Potential in Targeted Tumor Therapies Hendrik Fuchs Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Augustenburger Platz 1, 13353 Berlin, Germany; [email protected]; Tel.: +49-30-450-569173 Received: 23 September 2019; Accepted: 3 October 2019; Published: 11 October 2019 Abstract: Dianthin enzymes belong to ribosome-inactivating proteins (RIPs) of type 1, i.e., they only consist of a catalytic domain and do not have a cell binding moiety. Dianthin-30 is very similar to saporin-S3 and saporin-S6, two RIPs often used to design targeted toxins for tumor therapy and already tested in some clinical trials. Nevertheless, dianthin enzymes also exhibit differences to saporin with regard to structure, efficacy, toxicity, immunogenicity and production by heterologous expression. Some of the distinctions might make dianthin more suitable for targeted tumor therapies than other RIPs. The present review provides an overview of the history of dianthin discovery and illuminates its structure, function and role in targeted toxins. It further discusses the option to increase the efficacy of dianthin by endosomal escape enhancers. Keywords: dianthin; ribosome-inactivating protein; targeted toxin; immunotoxin; endosomal escape; cancer therapy; Dianthus caryophyllus L. Key Contribution: The present review provides an overview of the structure and function of dianthin and its potential as an attractive weapon in the fight against cancer when fused or coupled to tumor-specific ligands or antibodies. 1. Introduction Dianthin is the name for three homologous toxins obtained from the clove pink (Dianthus caryophyllus L.) and sweet William (Dianthus barbatus L.).
    [Show full text]
  • Saporin As a Novel Suicide Gene in Anticancer Gene Therapy
    Cancer Gene Therapy (2007) 14, 165–173 r 2007 Nature Publishing Group All rights reserved 0929-1903/07 $30.00 www.nature.com/cgt ORIGINAL ARTICLE Saporin as a novel suicide gene in anticancer gene therapy N Zarovni1, R Vago1,2, T Solda`3, L Monaco4 and MS Fabbrini5 Department of Biological and Technological Research and Cancer Immunotherapy and Gene Therapy Program, San Raffaele H Scientific Institute, Milan, Italy We used a non-viral gene delivery approach to explore the potential of the plant saporin (SAP) gene as an alternative to the currently employed suicide genes in cancer therapy. Plasmids expressing cytosolic SAP were generated by placing the region encoding the mature plant ribosome-inactivating protein under the control of cytomegalovirus (CMV) or simian virus 40 (SV40) promoters. Their ability to inhibit protein synthesis was first tested in cultured tumor cells co-transfected with a luciferase reporter gene. In particular, SAP expression driven by CMV promoter (pCI-SAP) demonstrated that only 10 ng of plasmid per 1.6 Â 104 B16 cells drastically reduced luciferase activity to 18% of that in control cells. Direct intratumoral injection of pCI-SAP complexed with either lipofectamine or N-(2,3-dioleoyloxy-1-propyl) trimethylammonium methyl sulfate (DOTAP) in B16 melanoma-bearing mice resulted in a noteworthy attenuation of tumor growth. This antitumor effect was increased in mice that received repeated intratumoral injections. A SAP catalytic inactive mutant (SAP-KQ) failed to exert any antitumor effect demonstrating that this was specifically owing to the SAP N-glycosidase activity. Our overall data strongly suggest that the gene encoding SAP, owing to its rapid and effective action and its independence from the proliferative state of target cells might become a suitable candidate suicide gene for oncologic applications.
    [Show full text]